1.Risk factors and mortality for carbapenem-resistant Acinetobacter baumannii bloodstream infection in elderly patients:a 10-year retrospective study
Ye XUE ; Chao-Shi ZOU ; Tai-Jie LI ; Mei-Xiang QIN ; Chan LIANG ; Kang-Hai LIU ; Dan-Ping QIU
Chinese Journal of Infection Control 2024;23(2):155-161
Objective To assess the risk factors for carbapenem-resistant Acinetobacter baumannii(CRAB)bloodstream infection(BSI)and 28-day short-term mortality in elderly patients,and provide reference for the pre-vention and treatment of CRAB BSI.Methods Clinical data of patients aged ≥60 years and diagnosed with AB BSI in a hospital in Yulin City from January 2013 to December 2022 were retrospectively analyzed,including demogra-phic and microbiological characteristics,as well as clinical outcomes of the patients.Variables which were significant in univariate analysis were selected for multivariate analysis using binary logistic regression model and Cox propor-tional hazards model.Independent risk factors for infection were further determined,and survival analysis was per-formed using Kaplan-Meier curve.Results A total of 150 patients were included in the study,out of which 16 pa-tients(10.7%)had CRAB BSI and 134 had carbapenem-sensitive AB(CSAB)BSI.The 28-day short-term mortali-ty of AB BSI in elderly patients was 15.3%(23/150,95%CI:9.6%-21.1%),and the short-term mortality of CRAB BSI was higher than that of CSAB([56.3%,9/16]vs[10.4%,14/134]).Deep venous catheterization(OR:15.598,95%CI:1.831-132.910)and combined infections of other sites(OR:15.449,95%CI:1.497-159.489)were related to CRAB BSI in elderly patients.The independent risk factors for 28-day mortality in elderly patients with AB BSI were hemodialysis(OR:11.856,95%CI:2.924-48.076),intensive care unit admission(OR:9.387,95%CI:1.941-45.385),and pulmonary infection being suspected source of bacteremia(OR:7.019,95%CI:1.345-36.635).Conclusion The occurrence of CRAB BSI in elderly patients is related to the combined infection of other sites and deep vein catheterization.Hemodialysis,admission to ICU,and pulmonary infection being suspected source of bacteremia are independent risk factors for the prognosis of AB BSI in elderly patients.
2.The Application of Lipid Nanoparticle-delivered mRNA in Disease Prevention and Treatment
Wei-Lun SUN ; Ti-Qiang ZHOU ; Hai-Yin YANG ; Lu-Wei LI ; Yu-Hua WENG ; Jin-Chao ZHANG ; Yuan-Yu HUANG ; Xing-Jie LIANG
Progress in Biochemistry and Biophysics 2024;51(10):2677-2693
In recent years, nucleic acid therapy, as a revolutionary therapeutic tool, has shown great potential in the treatment of genetic diseases, infectious diseases and cancer. Lipid nanoparticles (LNPs) are currently the most advanced mRNA delivery carriers, and their emergence is an important reason for the rapid approval and use of COVID-19 mRNA vaccines and the development of mRNA therapy. Currently, mRNA therapeutics using LNP as a carrier have been widely used in protein replacement therapy, vaccines and gene editing. Conventional LNP is composed of four components: ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG) lipids, which can effectively load mRNA to improve the stability of mRNA and promote the delivery of mRNA to the cytoplasm. However, in the face of the complexity and diversity of clinical diseases, the structure, properties and functions of existing LNPs are too homogeneous, and the lack of targeted delivery capability may result in the risk of off-targeting. LNPs are flexibly designed and structurally stable vectors, and the adjustment of the types or proportions of their components can give them additional functions without affecting the ability of LNPs to deliver mRNAs. For example, by replacing and optimizing the basic components of LNP, introducing a fifth component, and modifying its surface, LNP can be made to have more precise targeting ability to reduce the side effects caused by treatment, or be given additional functions to synergistically enhance the efficacy of mRNA therapy to respond to the clinical demand for nucleic acid therapy. It is also possible to further improve the efficiency of LNP delivery of mRNA through machine learning-assisted LNP iteration. This review can provide a reference method for the rational design of engineered lipid nanoparticles delivering mRNA to treat diseases.
3.The neuroprotective effect of W1302 on acute ischemic stroke in rats
Shao-feng XU ; Jiang LI ; Jie CAI ; Nan FENG ; Mi ZHANG ; Ling WANG ; Wei-ping WANG ; Hai-hong HUANG ; Yan WANG ; Xiao-liang WANG
Acta Pharmaceutica Sinica 2024;59(9):2539-2544
2-(4-Methylthiazol-5-yl) ethyl nitrate hydrochloride (W1302) is a nitro containing derivative of clomethiazole, which is a novel neuroprotective agent with both carbon monoxide (NO) donor and weak
4.Four new dammarane-type triterpenoid saponins from Gynostemma pentaphyllum (Thunb.) Makino
Guang YANG ; Hai-zhen LIANG ; Jie ZHANG ; Xiao-juan CHEN ; Bao-lin GUO ; Bai-ping MA
Acta Pharmaceutica Sinica 2024;59(8):2288-2294
Damarane-type triterpene saponins are the main active ingredients in
5.Osteogenic activity of magnesium loaded hydrogel core-shell microspheres by microfluidic chip in vitro
Long LI ; Hai LIANG ; Bin LIU ; Jian WU ; Jie ZHU ; Zhengjie LIN
Journal of Practical Stomatology 2024;40(3):351-359
Objective:To explore the osteogenic activity of in vitro cultured preosteoblasts treated by magnesium loaded hydrogel core-shell microspheres.Methods:A microfluidics chip device was designed and made to fabricate magnesium loaded hydrogel core-shell microspheres to precisely control the stable release of magnesium ions in vitro,the mechanism of controllable magnesium ion release in the promotion of osteogenic activity of MC3T3-E1 preosteoblasts was systematically investigated.Results:The magnesium loaded hydro-gel microspheres(PLGA/MgO-alginate microspheres)prepared by the microfluidics chip exhibited to be monodisperse with special core-shell structure and could control the stable release of magnesium ions at a concentration of 50 ppm in vitro.The in vitro study showed that it significantly enhanced the activity and proliferation ability of MC3T3-E1 preosteoblasts,promoted their osteogenic differ-entiation and mineralization ability,and increased ALP activity.Conclusion:Magnesium loaded hydrogel core-shell microspheres can promote the osteogenic activity of MC3T3-E1 osteoblasts in vitro.
6.Mechanism of Huayu Jiedu Decoction in Inhibiting Malignant Biological Characteristics of Multiple Myeloma
Zuo-Tao LI ; Hai-Liang LI ; Zhi-Min YAN ; Jie LIN ; Xiao-Yun CHEN ; Yan-Quan LIU ; Yi-Li WANG
Journal of Experimental Hematology 2024;32(5):1438-1443
Objective:To analyze and explore the effects of Huayu Jiedu Decoction on the malignant biological characteristics of multiple myeloma(MM)cells and its molecular mechanism,so as to provide experimental basis and theoretical basis for the alternative therapy of anti-MM in traditional Chinese medicine.Methods:Different concentrations of Huayu Jiedu Decoction were used to intervene myeloma U266 cells.The changes of cell proliferation activity were detected by CCK-8 assay,apoptosis was detected by Annexin V/PI double staining flow cytometry,and apoptosis and protein expression of related signaling pathways were detected by Western blot.Real-time quantitative PCR was used to detect mRNA expression changes of high mobility group protein B1(HMGB1),CXC chemokine receptor 4(CXCR4)and interleukin-6(IL-6).Results:Huayu Jiedu Decoction inhibited the proliferative activity of U266 cells and induced their apoptosis in a concentration and time dependent manner(r=-0.713,r=-0.827).After treatment with Huayu Jiedu Decoction for 48 h,the expressions of anti-apoptotic protein Bcl-2 and survivin were down-regulated,while the expression of pro-apoptotic protein Bax was up-regulated,and the phosphorylation level of TLR4/NF-κB signaling pathway was inhibited.After intervention of Huayu Jiedu decoction,the expressions of HMGB1 and IL-6 mRNA were significantly decreased,while the expression of CXCR4 was not significantly decreased.Conclusion:Huayu Jiedu Decoction can inhibit the proliferative activity of U266 cells and induce programmed death.Its molecular mechanism may be related to regulating the expression of apoptotic proteins,inhibiting the activation of TLR4/NF-κB pathway and down-regulating the expression of HMGB1 and IL-6 mRNA.
7.ZnO Quantum Dot and SnO2 Quantum Dot Labeling Antibodies and Single Particle Inductively Coupled Plasma Mass Spectrometry Coupled with Magnetic Immunoassay for Detection of Ovarian Cancer Biomarkers CA125 and HE4 in Human Serum
Yu-Pin CAO ; Hai-Ping CHEN ; Jie LIANG ; Bi-Yang DENG
Chinese Journal of Analytical Chemistry 2024;52(10):1562-1572
Ovarian cancer is one of the most fatal of all the gynecological malignancies.The detection of biomarker is one of the diagnostic bases for the disease.The combined detection of carbohydrate antigen 125(CA125)and human epididymis protein 4(HE4)in human serum can improve the accuracy of clinical diagnosis for ovarian cancer.In this study,a new method for analysis of ovarian cancer biomarkers CA125 and HE4 in human serum using zinc oxide quantum dot(ZnO QD)and tin oxide quantum dot(SnO2 QD)labeled antibodies coupled with single particle inductively coupled plasma mass spectrometry(ICP-MS)was developed.CA125 and HE4 antigens were captured by amino-modified magnetic nanoparticles combined with CA125 and HE4 primary antibodies.CA125 and HE4 secondary antibodies were labeled by ZnO QD and SnO2 QD,respectively.The signal frequency of Zn and Sn was determined by ICP-MS to realize the quantitative analysis of CA125 and HE4.The linear detection ranges of CA125 and HE4 were 0.02-200 U/mL and 0.02-100 ng/mL,the detection limits were 0.004 U/mL and 0.006 ng/mL(3σ),and the RSDs were 2.2%and 3.5%(n=6),respectively.This method had many advantages such as high sensitivity,good selectivity and less reagent consumption,and was successfully applied to determine the content of CA125 and HE4 in human serum.
8.Design of dilation incision device for neurosurgical procedures
Yu-Wei HAN ; Li-Gang CHEN ; Xin-Yu YANG ; Shun GONG ; Guo-Biao LIANG ; Hai JIN ; Jie-Yu LAI
Chinese Medical Equipment Journal 2024;45(10):37-40
Objective To design and evaluate a dilation incision device capable of facilitating stable support and flexible adjustment during neurosurgical procedures.Methods The dilation incision device was composed of a support plate,an adjustment assembly,a brain support ring,a rotation assembly,an electric motor,an expansion assembly and a neck support ring.The support plate was made of high-strength stainless steel;the adjustment assembly was made up of a first screw,a lifting groove,a slide bar and a nut;the brain support ring was fixed to the adjustment assembly through a support rod,with an outer layer of medical-grade silicone and an inner layer of stainless steel skeleton;the rotation assembly connected the brain support ring with the expansion assembly and consisted of a rotating shaft,a connecting rod and a rotating lug;a high-precision direct current servo motor was selected for the device;the expansion assembly included a spring,an expansion plate and a moving plate,which realized auto expansion or contraction through spring pressure;the neck support ring had its outer layer made of flexible polyurethane foam and inner layer being a stainless steel skeleton.The device had its stability and safety evaluated by static and dynamic tests at different heights(50,100,150 mm)and angles(0°,30°,60°),which was compared with the traditional fixation device to verify its application effect.Results Static and dynamic tests indicated the device showed high stability and safety in different heights and angles,and gained advantages over the traditional device in stability,convenient operation and surgical field visualization.Conclusion The device developed meets the requirements of neurosurgical procedures,and enhances the safety and portability of neurosurgical procedures.[Chinese Medical Equipment Journal,2024,45(10):37-40]
9.Mining and analysis of adverse drug reaction signals of melphalan based on FAERS
Panpan DI ; Hai LIANG ; Jie WANG ; Yunfei HU ; Shuyun JIA
China Pharmacy 2023;34(12):1493-1497
OBJECTIVE To mine the adverse drug reaction (ADR) signals of melphalan, so as to provide reference for clinically safe drug use. METHODS Using OpenVigil 2.1 data platform, relative ADR reports of melphalan from the first quarter of 2004 to the second quarter of 2022 in FAERS database were collected; data mining was conducted using the reported odds ratio (ROR) method and Medicines and Healthcare Products Regulatory Agency (MHRA) method of disproportional method. ADR reports were described and classified according to the system organ class (SOC) and preferred term (PT) in Medical Dictionary for Regulatory Activities (24.0 edition). RESULTS A total of 17 046 ADR reports related to the target drug melphalan were retrieved, and the number of ADR reports showed a fluctuating upward trend; the majority of patients were male (43.28%), and were concentrated between the ages of 50-<75 (35.09%), with the main reporting country being the United States (23.97%); ADR report involved a total of 22 842 severe outcomes, mainly including hospitalization or extended hospitalization (24.45%). Totally 403 ADR signals were detected, involving 23 SOC, mainly including blood and lymphatic system diseases (801 cases, 13.77%), followed by eye organ diseases (755 cases, 12.97%) and infectious and invasive diseases (716 cases, 12.30%). The ADR signals ranked high in the number of reported cases included febrile neutropenia, diarrhea, fever and mucositis and other PT; PT such as pneumonia, sepsis, vitreous hemorrhage, chorioretinal atrophy, myelodysplastic syndrome were not recorded in drug instructions. The ADR signals with high signal strength ranking included choroidal dystrophy, chorioretinal atrophy, eyeball atrophy and other PT, and above three types of PT were not included in the drug instructions. CONCLUSIONS ADRs caused by melphalan mainly include blood and lymphatic system diseases, eye organ diseases, and infectious and invasive diseases; before using melphalan, it is necessary to evaluate the drug use of patients, and pay close attention to the patient’s blood indicators and eye toxicity reaction, so as to guarantee the safety of treatment.
10.Tissue distribution of Qingfei Paidu Decoction based on HPLC-MS/MS.
Yan ZHANG ; Hai-Yu ZHAO ; Li-Xin YANG ; Yan-Yan ZHOU ; Bao-Lin BIAN ; Hua-Kai WU ; Hua-Ying ZHU ; Nan SI ; Peng-Fei LIN ; Liang WANG ; Hong-Jie WANG
China Journal of Chinese Materia Medica 2023;48(11):3074-3085
The tissue distribution of Qingfei Paidu Decoction was studied by HPLC-MS/MS in vivo. Hypersil GOLD C_(18) column(2.1 mm×50 mm, 1.9 μm) was used for gradient elution with acetonitrile as the mobile phase A and 0.1% formic acid solution as the mobile phase B. High-resolution liquid chromatography-mass spectrometry in both positive and negative ion scanning mode and multiple response monitoring(MRM) mode was employed to analyze the behaviors of the active components of Qingfei Paidu Decoction in diffe-rent tissues. The results showed that 19, 9, 17, 14, 22, 19, 24, and 2 compounds were detected in plasma, heart, liver, spleen, lung, kidney, large intestine, and brain, respectively. The compounds belonged to 8 groups, covering 14 herbs in the prescription. After administration with Qingfei Paidu Decoction, the compounds were rapidly distributed in various tissues, especially in the lung, liver, large intestine, and kidney. The majority of the compounds displayed secondary distribution. This study comprehensively analyzed the distribution rules of the main active components in Qingfei Paidu Decoction and provided a basis for the clinical application.
Chromatography, High Pressure Liquid
;
Tandem Mass Spectrometry
;
Tissue Distribution
;
Drugs, Chinese Herbal

Result Analysis
Print
Save
E-mail